Boundless Bio Appoints Jami Rubin as Chief Financial Officer

SAN DIEGO--(BUSINESS WIRE)-- Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced the appointment of Jami Rubin as Chief Financial Officer. Ms. Rubin brings more than 30 years of leadership experience in the biopharma industry as a top financial executive, equity analyst, investment banker, board member, and venture partner.

“Jami is a distinguished life sciences industry leader, and we are thrilled to welcome her to Boundless Bio,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “With our lead ecDNA-directed therapy, BBI-355, now in clinical development, Jami’s significant business acumen, operational expertise, and deep industry experience will help propel Boundless Bio as we enter our next phase of growth and seek to deliver potentially transformative new therapies to the more than 400,000 patients newly diagnosed in the US each year with previously intractable oncogene amplified cancers.”

"Despite recent advances in cancer therapeutics, a large percentage of patients with gene amplified cancers have limited options. Boundless Bio is pioneering an exciting new approach to addressing this large unmet need by developing ecDNA directed therapeutics. The first drug candidate from its ecDNA discovery platform is now in clinical trials," said Ms. Rubin. "Boundless Bio is led by world-class scientific founders and a proven management team and backed by top-tier investors. Together we have the potential to create a disruptive next generation precision oncology company and unlock a whole new vertical in cancer therapeutics."

Ms. Rubin was most recently Chief Financial Officer of EQRx, where she led the organization through a go public process that raised $1.35 billion. Ms. Rubin spent the majority of her career as a biopharma equity analyst, including as a Partner at Goldman Sachs where she led the healthcare business unit and ranked as a top pharmaceutical industry analyst. She also served as a Partner at PJT Partners, a global advisory-focused investment bank, where she provided strategic M&A, corporate finance, and capital-raising guidance for biotech and pharmaceutical companies.

Over the course of her career, Ms. Rubin has played key roles in significant corporate transactions, including spinouts and M&A, with leading pharmaceutical companies including Pfizer, Abbott, AbbVie, Eli Lilly, and Mylan. Ms. Rubin currently serves as a Venture Partner at ARCH Venture Partners and an independent board member and audit committee chair of Relay Therapeutics. She holds a B.A. in History from Vassar College.

About Boundless Bio

Boundless Bio is a clinical stage, next-generation precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies intended to improve and extend the lives of patients with oncogene amplified cancers. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is being evaluated in a Phase 1/2 clinical study and has multiple other pipeline programs advancing in preclinical development and discovery. In May 2023, Boundless Bio completed a $100 million Series C financing and has raised more than $250 million to date from leading life sciences investors.

For more information, visit

Follow us on LinkedIn and Twitter.

View source version on


James Lee, Boundless Bio

Dan Budwick, 1AB

Source: Boundless Bio

Back to news